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Abstract

mRNA vaccines for the prevention of infection disease have gained significant traction in the last
three decades, specifically with the recent emergency approval of two COVID-19 vaccines (Oliver,
Sara E et al., 2020; Rauch et al., 2018a). mRNA vaccines occupy a unique space in immunology
because of their utilization of cellular mechanisms to produce viral proteins, and their simplicity
and ease of manufacture (Cullis & Hope, 2017). These vaccines have shown strong humoral and
cell-mediated adaptive immune responses (Rauch et al., 2018b) . In addition, side effects of the
vaccines have been limited and subject response is manipulatable by varying the lipid nanoparticle
(LNP) vector of the vaccine (Sedic et al., 2018; Zhang, N. et al., 2020). This thesis will provide an
in-depth review of the types, mechanisms, and safety of mRNA vaccines, as well as a history of
mRNA technology and the current advancements of the field.
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mRNA Vaccinations for the Prevention of Viral Infections
Vaccines have saved countless lives over the centuries they have been in use, and
vaccinology is expanding as new technology and techniques are applied. Common forms of widely
used vaccines are live-attenuated viruses and inactivated viruses, which are weakened forms of the
virus that help the immune system of the body to recognize the virus without the pathogenicity that
actual infection would cause (Vaccine Types, 2017). Attenuation is the process of mutating or
weakening the virus to a form that is similar to the virus so that the immune system creates
antibodies against proteins found in the virus but does not rapidly replicate and harm the body
(Morrison & Plotkin, 2016). Like attenuated vaccines, messenger RNA (mRNA) vaccines provoke
an immune response by coding for an antigen that the target virus expresses but isolated from the
rest of the virus will not present illness (Zhang, C. et al., 2019). mRNA viruses are commonly
found in lipid coating to protect the mRNA from degradation in the body, although there are
several methods of mRNA delivery in use (Cullis & Hope, 2017).
mRNA vaccines have shown great potential in stimulating immune cells and responses are
highly manipulable through gene editing for specific protein epitomes. Recently, COVID-19
mRNA vaccines have entered circulation and have shown great success at preventing infection
(Oliver et al., 2020; Oliver, Sara E., 2021). mRNA vaccinology continues to expand, proving in
many cases to be more cost-effective and easier to produce than their counterparts (Jackson, N. A.
C. et al., 2020). Recent studies in self-amplifying mRNA vaccines, which can use vaccine
transcriptional proteins to increase antigen expression, have shown high levels of immunogenicity
with fewer vaccine particles compared to conventional mRNA vaccines (Stokes et al., 2020). This
thesis will examine the types, mechanisms, history, and safety of mRNA vaccines, as well as
assess the current state of mRNA vaccinology.
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History of mRNA Vaccination

Vaccination is a centuries old practice, originating with the work of Edward Jenner to
vaccinate for smallpox and Louis Pasteur’s Germ Theory (Zhang et al., 2019). These vaccines
were simple but remarkable, using various methods to familiarize the body to a pathogen without
overwhelming the immune systems defense. Jenner and Pasteur did not even know the structure or
nature of the bacteria and viruses under investigation, although effective treatments were
developed through observation and trial and error. Vaccination has helped the world through dark
times and has helped with the eradication of several diseases (Hajj Hussein et al., 2015). However,
some diseases continue to evade defeat via vaccination, thus there remains a continuous effort to
develop new vaccination methods and find unique strategies to outsmart the new and emerging
pathogens. These persistent pathogens such as HIV (human immunodeficient virus) have been the
catalysts for mRNA vaccine technology.
mRNA vaccine technology has followed DNA vaccines as well as subunit and vaccines.
DNA vaccines suffer from complications due the additional step of transcription required before a
protein can be produced, as well as safety concerns to their integration in the nucleus (Zhang et al.,
2019). Subunit vaccines lacked the potent immune response that mRNA vaccines have been found
capable of (Zhang et al., 2019). Another appeal of the mRNA vaccine was its simplicity, which has
the possibility of quick manufacture during epidemic situations like COVID-19 (Pardi, Hogan et
al., 2018).
The LNP was already in widespread use in studies to transport siRNA for gene silencing,
so finetuning the lipids for mRNA was an easy task (Pardi et al., 2018). Groundbreaking research
in the 1990s provided the understanding for mRNA modification that allowed mRNAs to be stable
enough to facilitate effective protein expression (Zhang et al., 2019). Since then, research into
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mRNA vaccines has increased exponentially. mRNA vaccination has also been spurred on by
possibilities of cancer therapy, which represents the other main interest in mRNA vaccines aside
from infectious disease (Fiedler et al., 2016). mRNA vaccines can produce any protein in the body
if the sequence is known, which allows mutant cancer proteins to be targeted for the specific
destruction of cancer line cells.
Prior to the vaccines to 2020’s COVID-19 vaccines, no mRNA vaccine had been approved
by the US Food and Drug Administration (FDA) (Oliver et al., 2020). However, due to the urgent
need for a vaccine and funding under Operation Warpspeed, Pfizer/BioNTech’s vaccine was
approved for use on December 11th, 2020 (Sahin et al., 2020). mRNA vaccine technology
continues to improve and now that the COVID-19 vaccines have set precedence for mRNA
vaccine development, more mRNA vaccines are sure to follow.
Divisions of mRNA Vaccines
Current mRNA vaccines fall into the four following divisions or categories: naked mRNA
vaccines, lipid nanoparticle (LNP) protected mRNA vaccines, charge-altering releasable transport
(CART) mRNA vaccines, and capsid-coat mRNA vaccines. Each class has shown promise and
utility in some capacity for preventing infectious disease, and selection of a vaccine type can be
pathogen dependent.
Naked mRNA vaccines consist of a vaccine where the mRNA is not accompanied by any
type of protective coat. These types of vaccines have been shown to be effective at producing
protein expression in local tissues of mouse and human skin (Probst et al., 2007). In this manner,
the protein is expressed on MHC (major histocompatibility complex) I molecules and targeted by
helper and cytotoxic T cells. One downside of the naked mRNA vaccine is the lack of humoral
response triggered. Unless the host cell secretes the translated protein of interest, there will not be
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any B cell interaction and no antibody response (Sahin et al., 2014). Without the ability to quickly
produce IgG antibodies through activated B cells, a severe infection could still occur after
immunization.
There is evidence that there are specific mechanisms that control the transport of nucleic
acids through the cell membrane in a transport process that is mediated by calcium, as an increased
calcium concentration in the mouse vaccine by Probst et al. showed an increase in protein
expression (Probst et al., 2007). This type of local injection of naked mRNA is somewhat limited
in its effect because mRNA has a short half-life in the extracellular matrix and injection to a tissue
group only produces local protein expression (Probst et al., 2007; Sorrentino, 1998). To stimulate
an immune response, it is necessary for the translated proteins to be presented on MHC molecules
so that T cells can be activated to produce adaptive immunity to the antigen, and therefore the
associated pathogen.
Because the dermis lacks a high concentration of antigen-presenting cells (APCs), it is
necessary to inject the mRNA into a tissue with a higher APC presence or utilize an adjuvant to
effectively recruit greater amounts of dendritic cells and lymphocytes. For this reason, naked
mRNA has also been used for stimulation of the mouse immune system intranodally (Kreiter et al.,
2010). These intranodal injections of mRNA produce increased levels of T cells, interlukin 2 (IL2),
and activated natural killer (NK) cells, as well as the mRNA-coded protein of interest (Kreiter et
al., 2010). Additionally, the intranodal injections in mice were shown to have produced memory T
cells against the antigen in question, conferring cell mediated immunity (Kreiter et al., 2010). The
use of naked mRNA is limited, but intranodal injections show great potential for producing cell
mediated immunity against specific antigens.
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Because mRNA degrades rapidly in certain unfavorable conditions and is not suited for
survival outside of its intended environment in the cell nucleus and cytoplasm, protecting the
mRNA via a delivery vector can increase the immune response to the vaccine by ensuring more
mRNA is taken up by the host cells. Therefore, just as a virus uses a protein or a lipid coat to
protect its genetic material from the extracellular matrix, mRNA vaccines can be modified to better
withstand the environment in the body (Sedic et al., 2018). A lipid nanoparticle coat has been used
to protect mRNA particles for exogenous protein production in rat and monkey models with
successful and safe treatment (Sedic et al., 2018). Historically, liposomes have been used to
transport anti-cancer drugs to tumor tissues. These liposomes are particularly effective types of
LNPs because of their size of <100 nm and the neutrality of the charge of the extracellular portion
of the molecule, preventing the integration of proteins via charge-driven interactions (Cullis &
Hope, 2017). As of 2017, there were 9 intravenous LNP drugs approved for treatment.
Unfortunately, liposomes are ineffective at encapsulating genetic material due to the size and
negative charge of the phosphate backbone of nucleic acids (Cullis & Hope, 2017).
Cationic lipids were proposed due to the positive charge they possess, which could
associate with the negatively charged RNA (Cullis & Hope, 2017). Cationic lipids alone are
unsuitable for in vivo genetic material delivery because they have a positive surface charge that
causes instability and toxicity in the host (Cullis & Hope, 2017). Eventually, an ethanol-loading
process was devised together with a mixture of lipids which gave the best of both worlds: an LNP
with a cationic interior and a neutral exterior (Cullis & Hope, 2017). Polyethylene glycol (PEG)
lipids are used to obtain the outer shell, while a mixture of structural lipids and cationic lipids form
the inner, inverted capsules that surround the genetic material (Cullis & Hope, 2017). These LNPs
were especially effective at delivering short interfering RNA (siRNA) to the liver because
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hepatocytes express apolipoprotein E (ApoE), which has been shown to adsorb to the LNP and
target it for endocytosis (Cullis & Hope, 2017). Once inside the cell, the cationic lipids are
protonated and attract the anionic lipids of the endosome, causing the release of the genetic
material into the cytoplasm (Figure 1). The effectiveness of this pathway into the cell is limited
without ApoE, causing a significant roadblock for LNP-vector treatments in the future (Cullis &
Hope, 2017).

removed for copyright

Figure 1. LNP-facilitated mRNA release. The negatively charged mRNA associates with the
cationic lipids during LNP formation. Upon phagocytosis, the low pH of the vesicle induces
negative charges of the membrane lipids, causing a reaction between the cationic lipids of the LNP
and the anionic membrane proteins, causing a fusing of the lipids and the release of the mRNA into
the cytoplasm. (Cullis & Hope, 2017).
An alternative to LNPs are charge-altering releasable transporters (CARTs). CARTs are
like LNPs in that a charge-directed mechanism is used to release their contents into the cytoplasm.
Oligo (carbonate-b-α-amino ester)s are the molecules that make up the complex with negatively

MRNA VACCINATIONS

10

charged mRNA (McKinlay et al., 2018). The CARTs are complexes where the cationic amino
groups stabilize the large, negative mRNA molecules, allowing the mRNA to travel through the
body in a protected fashion (McKinlay et al., 2017). Once the CART complexes have reached the
membrane, endocytosis occurs, and under a pH dependent reaction the amino groups are
neutralized to amide groups, losing their positive charge and ability to stabilize the mRNA, causing
the dissociation of the mRNA molecules (McKinlay et al., 2017). The amide groups detach and
cyclize to form small neutral molecules that are easy and safe for the host cell to degrade, resulting
in an efficient mRNA delivery without some of the toxic side effects of LNP delivery (McKinlay
et al., 2017).
The manipulation of the type of lipid and the number of carbonate and amino groups used
can be manipulated to suit the target cells or the size of mRNA being transfected (Haabeth et al.,
2018). Additionally, the ratio of CART molecules to mRNA molecules can be manipulated for the
best rates of translation, based upon the treatment type and the desired effect (McKinlay et al.,
2017; McKinlay et al., 2018). Another useful aspect of the CART delivery method is the ability to
incorporate adjuvant directly into the delivery complex, to ensure the highest doses of adjuvant to
the cells receiving the mRNA for protein translation. Addition of CpGs, promotor regions with
cytosines followed by guanines, increases immunogenicity of the vaccine. CPGs are recognized by
Toll-like receptor-9 (TLR9), an receptor that adheres to common viral RNA sequences, which
increases the APC expression of the translated antigen by MHC molecules and causes a strong
cytotoxic T cell response (Haabeth et al., 2018).
A capsid coat is a protective layer of proteins that some viruses use to protect their genomic
material. The viruses can self-replicate by encoding the proteins that constitute the protein coat and
replicate in infected cells. This virus machinery can also be used to create mRNA vaccines that are
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able to infect cells efficiently, but the mRNA can be manipulated so that no further infectious
particles form, because the propagation of these virus particles is responsible for the fever,
inflammation, and other symptoms associated with infection. One study was conducted with the
Semliki Forest Virus (SFV) vector, to confer immunity to an influenza strain in mice (Zhou et al.,
1994). The authors of the study infected cell cultures with two mRNA strands simultaneously, one
coding SFV proteins and the other coding influenza protein (Zhou et al., 1994). The mRNAs were
manipulated so that only the influenza protein was tagged for incorporation into the capsid coat
(Zhou et al., 1994). This modification insured that these new virus particles would not continue to
replicate in newly infected cells (Zhou et al., 1994). In mice, these new virus particles were
successful in producing anti-influenza IgG antibodies and cytotoxic T-lymphocytes (Zhou et al.,
1994). Proteins that make up the capsid coat of a virus can be effective targets for the immune
system since these proteins are exposed and accessible to cells of the immune system.
Mechanisms
To effectively serve as vaccine agents, mRNA vaccines need to facilitate effective delivery
to the cytoplasm of target cells, whether they be APCs such as dendritic cells or muscle tissue. As
most vaccines are delivered intramuscularly, the muscle tissue and surrounding immune cells are
the targets of the vaccine. LNP-encapsulated vaccines function by undergoing endocytosis by the
target cells. Once encapsulated by the target cell, the cationic lipids which form the LNP interact
with the negatively charged endosomal membrane to facilitate the release of the contents of the
LNP (Tan & Sun, 2018). The low pH of the endosome causes the ionization of the cationic lipids;
without the low pH of the endosome to facilitate release of the mRNA, the LNP would not be
triggered to release the mRNA (Tan & Sun, 2018). If the LNP were ionized at too high a pH, it
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would be too unstable to be dependable and could deteriorate at physiological pH, failing to reach
the target cell cytoplasm (Tan & Sun, 2018).
The idea behind the ribosomal translation of the vaccine-borne mRNA is that by the time
the mRNA has been released from the LNP, it is indistinguishable from the host’s own mRNA
(Wadhwa et al., 2020). Thus, the cell will indiscriminately translate the mRNA into its coded
peptide chain and fold the protein as if it were a native protein. Although the mRNA can have
modified bases, tails or caps, because these structures are modeled after human mRNA, the cell
machinery is able to effectively translate and fold the in-vitro synthesized (IVT) mRNA (Wadhwa
et al., 2020). To boost the half-life of the mRNA during this naked stage, the mRNA can be
modified using tails or caps to avoid rapid degradation by RNase. These modifications will be
explored in more depth later.
Once the vaccine antigen has been translated by the cell, the cell will attempt degrade the
protein via proteosomes, because the protein will not contain a signal peptide (Wadhwa et al.,
2020). The signal peptide is the cells normal mechanism of determining the destination of the
newly synthesized protein: cell membrane, extracellular matrix, or cytoplasm. The proteosome will
degrade the protein into its peptide epitomes, which will be bound by MHC class I molecules,
which, in turn, present the antigen at the surface of the cell and allow for the recognition of the
antigen by T cells, with their matching T-cell receptors (TCRs) (Wadhwa et al., 2020).
To have an effective antibody response via humoral immunity, it is necessary for the
antigen to exit the cell and be taken up APCs with MHC II. Once the antigen epitomes are bound
to MHC II, recognition by naïve B cells is possible and a humoral response can be mounted against
the antigen (Rauch et al., 2018). One mechanism for this MHC II expression is through the
phagocytosis of the infected cell via an APC, such as a dendritic cell (Rauch et al., 2018). Because
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the mRNA and other vaccine components trigger the TLRs of the cell, other immune cells such as
dendritic cells are recruited to deal with the potential infection and to phagocytose compromised
cells.
Once the cell has been phagocytosized, the contained antigen can be processed and
presented on MHC class II molecules to produce the humoral immunity response, which will
enable antibody production against the pathogen (Rauch et al., 2018). In addition to the phagocytic
pathway of dendritic cells, a secretion peptide signal can be attached to the mRNA sequence of the
antigen (Sahin et al., 2014). Upon folding the protein, the cell will package the antigen for release
to the extracellular matrix, where in can be encountered by APCs capable of MHC II expression
(Sahin et al., 2014).
Adjuvants are elements that are added to a vaccine to enhance the immune response to the
vaccine. By amplifying the response, a more complete protection can be afforded, possibly
negating the need for additional rounds of vaccination or booster shots. Adjuvants function by
leveraging the mechanisms the innate immune response has available to detect and counter
pathogens. To detect the presence of foreign invaders, the body uses pattern recognition receptors
(PRRs) to recognize common invasive agents. PRRs such as Toll-like receptors (TLRs) can
identify proteins or other molecules that are unique to bacteria or viruses that are not expressed by
the body, to avoid auto-immune responses (Edwards et al., 2017). Genetic material can also serve
as an activator of TLRs, so genetic material in the form of an mRNA vaccine can serve as a selfadjuvant to TLRs 7 and 8 (Kawai & Akira, 2009). This feature explains the efficiency and
simplicity of mRNA vaccines; their very own genetic material increases their immunogenicity,
mimicking virus pathology. One study performed with hemagglutinin mRNA from influenza A
showed that TLR activity was upregulated in association with mRNA vaccine injection in mice,
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supporting the theory that TLRs are involved in the immunogenicity of mRNA vaccines (Pardi,
Parkhouse et al., 2018).
Additionally, it is possible to add additional small molecules to the vaccine which produce
more potent immune responses. One study, utilizing the TLR activator R848 incorporated into a
mRNA vaccine, found heightened specific cell-mediated immune response to the mRNA in
question (Islam et al., 2021). Cytosine phosphoguanine (CpG) synthetic bases have been
thoroughly utilized as vaccine adjuvants, and are recognized by TLR9, which is an endosomal
PRR that is prevalent in dendritic cells which are crucial in adapted immunity through MHC
presentation (Coffman et al., 2010).
Another form of mRNA protection is nucleotide substitution. Pyrimidine nucleotides such
as 1-methylpseudouridine triphosphate and 5-methylcytidine triphosphate have been used as
substitutions for the uracil and cytosine respectively to prevent recognition by TLRs (Sedic et al.,
2018). RNase is secreted by the pancreas and various other tissues throughout the body to degrade
RNA specifically in the body, by catalyzing the hydrolysis of the phosphodiester bonds that form
the backbone of the RNA molecule (Sorrentino, 1998). These RNase enzymes contribute to the
short half-life that mRNA molecules display in the cytoplasm. The mechanisms to protect mRNAs
and inhibit the activity of RNase enzymes in the cytoplasm of the cell are numerous and complex,
and these mechanisms are dependent on the post-transcriptional modification of the mRNA
(Houseley & Tollervey, 2009).
The addition of a Poly-A tail, a 150-250 nucleotide repetition of adenine nucleotides, at the
3’ end of the molecule is one mechanism that the body uses to increase the stability of the mRNA
(Houseley & Tollervey, 2009). Polyadenylation has been used during modification of exogenous
mRNA to increase its half-life in the cytoplasm of the cell. Untranslated region (UTR)
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modification on the 3’ and 5’ ends of the coding regions can be used to increase translation rate
and regulate the transport of the newly formed protein (Sahin et al., 2014) Eukaryotic mRNA can
be post-transcriptionally modified to contain a 7-methylguanosine cap which aids in translation by
its interaction with translation initiation factor 4E (Sahin et al., 2014). Using the viral enzyme
mRNA guanyl transferase, addition of a 7-methylguanosine cap to the 5’ end of IVT mRNA can
be achieved, mimicking the structure of native post-transcribed mRNA without incorporation of
the IVT mRNA into the cell’s nucleus (Martin et al., 1975).
Coronavirus
The U.S. government worked to fund 5 vaccine candidates to prevent the spread of
COVID-19 under an initiative termed Operation Warp Speed ((ASPA), Assistant Secretary for
Public Affairs, 2020; Brüssow, 2020). Out of the five vaccine candidates which were part of the
program, two were classified as mRNA vaccines (Brüssow, 2020). Moderna and Pfizer developed
these two vaccines that utilized mRNA coding for the same spike protein (S), to stimulate an
immune response (Brüssow, 2020). The methods used by these developers to effectively stimulate
an immune response is discussed below.
Both BioNTech/Pfizer and Moderna vaccines use the same general formula: a LNPencapsulated mRNA strand encoding the 1,273 amino acid spike protein. Moderna’s vaccine,
mRNA-1273, consists of mRNA for the S-2P antigen from SARS-CoV-2 (the novel COVID-19)
virus (Jackson, L. A. et al., 2020). The basic structure of the vaccine is an LNP-encapsulated
mRNA diluted with saline (Jackson et al., 2020). A mixture of 4 lipids was used, although the
formula of the lipids was not disclosed in the preliminary Phase 1 trial report (Jackson et al., 2020).
Phase 1 trials were initiated in a record time frame, due to the current crisis caused by
COVID-19 (Chung et al., 2020). The vaccine manufacturing-process used several techniques
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previously mentioned, and mRNA substitutions were made so that a particular stable conformation
of the S protein would be expressed which would stimulate a strong immune response to the native
protein found on the SARS-CoV-2 virus (Graham et al., 2019; Jackson et al., 2020). The S protein
has a sequence of 1,273 amino acids, with a 222 amino acid receptor-binding domain (RBD)
which associates with angiotensin-converting enzyme 2 (ACE2) in humans (Hu et al., 2020). Other
known non-pathgenic SARS-CoV viruses differ in some residues in the receptor binding domain
(RBD); these mutations in SARS-CoV-2 increase the affinity of S protein for the ACE2 protein
(Hu et al., 2020). The mRNA-1273 vaccine contained a modified mRNA code where the amino
acid residues at positions 986 and 987 had been changed to proline residues to cement the
translated protein in the prefusion conformation, as the protein undergoes a conformational change
when bound to its receptor (Chung et al., 2020; Graham et al., 2019; Jackson et al., 2020). mRNA1273 has a modification in one of the RBD domains of the S protein to maintain the prefusion
conformation (Figure 2).
Isolating the protein in its prefusion state is imperative because the antigen encoded by the
mRNA must have the same structure as the conformation of the virus protein upon viral entry so
that antibodies created can neutralize the virus. Moderna does not report the use of an adjuvant in
their vaccine, although mRNA itself functions as a PAMP through recognition by TLRs 7 and 8,
perhaps increasing the immunogenicity of the vaccine. Additionally, some LNPs can be potent
adjuvants, so it is possible that Moderna utilized lipids as an adjuvant for their vaccine (Perrie et
al., 1987). Moderna also mentions chemical modification of the mRNA to prevent premature
detection by the body, although the nature of the modifications is not specified (Jackson et al.,
2020). Perhaps some nucleotide substitutions were used as previously described to prevent
elimination by TLRs (Sedic et al., 2018).
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Figure 2. COVID-19 S protein structure. The structure of the spike protein of the COVID-19
virus was obtained via cryo-electron microscopy (cryo-EM) imaging, and the results were
published on the 13th of March 2020, allowing vaccine manufacturers to quickly tackle the task of
vaccine production (Wrapp et al., 2020). The spike protein is a trimeric protein, with its subunits
denoted as S1, S2, and S3 (Wrapp et al., 2020). The conformation as seen above is in the prefusion
state, which is distinguishable from the other conformations of the protein by the position of the
RBDs. The S1 RBD (green) undergoes a hinging motion upon receptor binding that facilitates viral
adhesion (Wrapp et al., 2020). “Structure of 2019-nCoV S in the prefusion conformation” by
Wrapp et al. is licensed under CC BY 4.0.
The U.S. Food and Drug Administration (FDA) approved use of the Moderna vaccine on
December 18th, 2020 (Oliver, 2021). This was after reviewing the phase III vaccine trial that was
carried out in a double-blind study of 30,000 participants, across race, age, and gender, and
secondary medical conditions were also present (Mahase, 2020). The trial resulted in a 94.1%
efficacy rate at preventing symptomatic infection of COVID-19 (Oliver, 2021). The vaccine is also
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likely to offer protection from asymptomatic transmission, which is important for the development
of herd immunity to the virus. Due to the recent nature of the study, it is impossible to tell the
length of immunity and whether booster vaccines will be required for continued protection to the
vaccine. The symptoms of the vaccine itself were mild, with only 1% of participants reporting
severe reaction (Oliver, 2021). The vaccine requires two doses, spaced 4 weeks apart (Oliver,
2021). One benefit of the Moderna vaccine is that it can be safely stored in a freezer for long-term
storage or in a refrigerator for up to 30 days, which aids in the distribution of the vaccine (Mahase,
2020).
The BioNTech-Pfizer vaccine, BNT162b2, is also an LNP-encapsulated mRNA vaccine
encoding the spike protein in its prefusion state (Walsh et al., 2020). Pfizer’s vaccines contain the
lipids ALC-0315 and ALC-0159 and cholesterol (Polack et al., 2020). ALC-0135 serves as the
cationic lipid, assisting in the formation of the LNP around the negatively charged mRNA (Polack
et al., 2020). Inside the cell, ALC-0315 allows the mRNA to be released from the endosome due to
electrostatic interactions between the lipid and the endosomal membrane (Polack et al., 2020).
ALC-0159 is the structural PEG lipid for the LNP, and cholesterol also aids in the formation and
regulation of the size of the LNP (Polack et al., 2020). BioNTech-Pfizer were originally
researching 4 different vaccines for COVID-19, including BNT162b1, which contained only
partial S protein code (Walsh et al., 2020). Although BNT162b1 resulted in similar immune
response compared to BNT162b2, BNT162b2 was pursued in phase II/III trials due to its lower
symptomatic response in participants during phase I trials (Walsh et al., 2020). BNT162b2 also
contained N1-methylpseudouridine nucleosides to increase the half-life of the mRNA in the cell
cytoplasm (Polack et al., 2020). Pseudouridine, in place of uridine, offers higher translational
capacity and avoids or limits detection by TLRs (Karikó et al., 2008). Research shows that
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BNT162b2 also confers immunity to 19 different pseudoviruses, with unique mutations to the
RBD of the virus (Sahin et al., 2020). If COVID-19 can perform antigenic drift, leading to
mutations of the S protein, it is imperative that the vaccine offers protection to novel strains of S
protein, so this data is very encouraging.
The BioNTech-Pfizer vaccine was approved for use by the FDA on December 11th, 2020,
less than 11 months after the genetic information of the coronavirus was released (Oliver et al.,
2020; Polack et al., 2020). Like Moderna’s vaccine, BNT162b2 requires two doses, with 28 days
between doses (Oliver et al., 2020). This vaccine has a reported efficacy rate of 95% in its phase III
trial, with 43,548 total participants, with diverse race, gender, ethnicity, and health conditions
represented (Oliver et al., 2020). The efficacy rate among all the distinguished subgroups was
above 92%, and serious adverse effects were below 1% (Polack et al., 2020). The BioNTech-Pfizer
vaccine requires storage at −70°C, making it more difficult to transport and distribute compared to
mRNA-1273 (Mahase, 2020).
Safety and Ethics
The novelty of mRNA vaccination combined with the emergency approval of the recent
COVID-19 mRNA vaccines has left questions as to whether these vaccines are safe and if there are
detrimental side-effects to the vaccines. mRNA vaccines are introducing the body to foreign
material including modified nucleosides and lipids (Jackson et al., 2020). The immune system does
recognize the material as foreign which is the reason for the inflammation or pain that is sometimes
associated with vaccination (Sedic et al., 2018). These are necessary for immune system
stimulation, and if the lipids and mRNA modifications are present in the correct concentrations, the
danger of adverse reactions can be mitigated. The safety risks associated with mRNA vaccines are
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inherent in all vaccine forms; vaccines necessarily must introduce foreign material into the body to
stimulate an immune response.
Although mRNA vaccines are introducing the body to an element of a pathogen, there is no
danger of contracting the disease since the mRNA is only coding for a single protein or a subunit
of a single protein. There is no risk of viral infection associated with mRNA vaccines. Another
benefit of mRNA vaccines is the body’s eventual elimination of the mRNA. Because viruses often
have single or double-stranded RNA genomes, the body has RNAase and TLRs to recognize and
neutralize foreign mRNA (Sahin et al., 2014). This makes mRNA inherently fragile and short-lived
in the cytoplasm of cells. mRNA modification such as poly-A tails and nucleoside modification
give vaccine developers some room for modification to fine-tune the half-life of mRNA in
vaccines (Jackson et al., 2020). If the vaccine is well-tolerated, the longer the half-life the better
because more protein will be produced, allowing for greater immunogenicity.
Because the cells which are infiltrated with mRNA will present the material on MHC I or II
molecules, these cells with be targeted for apoptosis by the immune system (Zhang et al., 2019).
Unlike viruses, however, there are a limited number of mRNA molecules injected, and these
molecules cannot propagate like viruses. To create an effective, safe vaccine, the balance between
safety and strong immune system simulation must be struck. By modifying the lipid structure and
LNP size, safe and effective vaccines can be produced, as demonstrated by recent COVD-19
mRNA vaccines.
A phenomenon known as antibody dependent enhancement (ADE) complicates the
functionality of some vaccines (Arvin et al., 2020). In some viruses, the binding of antibody to the
virus at the Fab region (the antigen-binding fragment of immunoglobins) can enhance the affinity
of cell receptors for viral antigens (Arvin et al., 2020). In cases like these, antibody formation to a
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viral antigen can enhance the pathogenicity of a virus during a secondary infection (Arvin et al.,
2020; Lazo et al., 2007). To protect against these pathogens, targeting cell-mediated immunity is
preferred, since cell-mediated immunity offers specificity without the use of antibodies. One study
explored the ability of infection of one of the protein coat serotypes of the dengue virus to protect
against the dengue virus (Lazo et al., 2007). This protein-based vaccine was preferred for the
dengue virus since the protein coat of the virus is surrounded by a lipid membrane embedded with
glycoproteins (Lazo et al., 2007). Since the capsid protein is not exposed on the surface of the cell,
no humoral response to the protein occurs; only MHC presentation, leading to a cell-mediated
response (Lazo et al., 2007). The potential for an ADE response to a vaccine complicates the
formation of some mRNA vaccines. The mechanisms of ADE are not well understood, and further
studies need to be done to understand the inconsistencies that have been seen in the study of ADE
for certain pathogens.
Current Developments and Future Opportunities in mRNA Vaccine Technology
The recent success of COVID-19 mRNA vaccines has shown the scientific community that
mRNA vaccines are not only viable drugs, but that under the right conditions, mRNA therapeutics
can be synthesized quickly and economically due to their relative simplicity. The COVID-19
vaccines discussed previously have opted for LNP vectors of mRNA vaccine delivery, which
seems to be ideal for intramuscular delivery, which has been conventional for almost all injectable
vaccines. In the future, however, there may be the possibility of intravenous or intranodal
injections, which could be used to target specific tissues or systemic vaccine delivery (Huang et al.,
2020). Because most research up to this point regarding mRNA vaccines has used intramuscular
vaccination, these other administration routes could be researched. Perhaps LNPs will remain
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effective vectors when tested in new tissues, although it is possible that LNPs will need adjusting
or new delivery routes will need to be explored (Huang et al., 2020).
Among the exciting new advancements of mRNA vaccines is the potential for making new
vaccines to the seasonal flu. The current flu vaccines are inactivated or live-attenuated and are
more difficult and time-consuming to produce than mRNA vaccines (Alameh et al., 2020).
Additionally, a recent study showed that an mRNA vaccine in mice, targeting the hemagglutinin
spike of the influenza virus, was able to offer protection against more than one unique strain of the
flu (Pardi et al., 2018). This broader protection of the vaccine would be valuable given the
volatility of the flu proteins (Alameh et al., 2020). Due to the annual nature of the flu season, the
rapid timeline of mRNA vaccines would be invaluable. Once an effective formula for the flu is
prepared, fighting the flu could become a case of “plug-and-chug” vaccine manufacturing that
would only vary in the specific mRNA sequence for the current year.
mRNA vaccine technology is also being tested for use against HIV, although it has proven
difficult to produce neutralizing antibodies to HIV envelope protein through any vaccine model
(Alameh et al., 2020). One recent study was able to produce high levels of antigen-specific IgG in
monkeys through mRNA vaccination, but despite the high titers against the envelope protein, the
effective immune response was limited to half of the vaccine subjects (Pardi et al., 2019). Future
research is certainly needed regarding HIV, due to the evasive nature of the virus.
Among the other recent advancements in mRNA vaccine development is a potential
vaccine against the herpes simplex virus type 2 (HSV-2), the STD behind genital herpes. A 2019
study in guinea pigs using a trivalent mRNA vaccine which encoded three separate virus
glycoproteins showed that high titers of antibodies against each of the proteins was achieved
(Awasthi et al., 2019). This vaccine had higher titers than other subunit vaccines that proceeded to
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human trials, so this vaccine has the potential to become the first vaccine against HSV-2 (Awasthi
et al., 2019). The multivalent character of this vaccine is also worth noting because other vaccines
with multiple different surface proteins could also be attacked in a similar multivalent fashion,
increasing the protection afforded by the vaccine. The flu vaccine particularly could be targeted in
this fashion since the hemagglutinin and neuraminidase proteins each contribute to the virus’s
pathogenicity and are specific antibody targets.
Self-amplifying viruses were mentioned previously, although the self-replication
mechanism is promising and worth examining in greater detail. The basic premise of the selfamplification process is using virus structures and mechanisms to promote vaccine efficacy
(Maruggi et al., 2019). RNA viruses in their wild-type form contain cellular machinery to often
interfere with cell function or to promote the translation of virus mRNA over cell mRNA (Maruggi
et al., 2019). Self-amplifying mRNA vaccines contain mRNA for structural virus proteins that
facilitate the promotion and replication of virus mRNA (Maruggi et al., 2019). In this manner, selfamplifying viruses can produce several times the number of mRNA of interest compared to
conventional mRNA vaccines, increasing the immune response to the protein. Although selfamplifying vaccines are using virus technology to amplify, the virus proteins that cause the
propagation of additional virus particles that are associated with viral infections have been
removed or mutated so that there is no risk of infection (Stokes et al., 2020). The key differences
between conventional and self-amplifying mRNA vaccines can be seen in Figure 3.
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Figure 3. Conventional mRNA vaccine vs Self-Amplifying mRNA. Self-amplifying mRNA
vaccine particles share similar structures with convention mRNA particles, with the key difference
being the presence of additional virus-derived mRNA coding for replicating proteins, indicated
above as nsPs (non-structural proteins). Once the cell’s machinery has translated these replicating
proteins, the proteins for replicating centers that are able to duplicate the mRNA of interest so that
cellular ribosomes can translate all these copies into the protein of interest (Maruggi et al., 2019).
“Schematic Representation of mRNA Vaccines and Mechanism of Antigen Expression” by
Maruggi et al. is licenced under CC BY-NC-ND 4.0.
One 2020 study on a self-amplifying mRNA vaccine for rabies in rats showed that the
vaccine had no significant increased risk to the rats compared to responses to conventional
vaccines (Stokes et al., 2020). In addition, the protein-of-interest mRNA was found in the lymph
nodes of the rats 1-day post-immunization, indicating that the vaccine had been transported
to the lymph nodes, which is where APCs present antigen to B and T-cells (Stokes et al., 2020). An
IgG response to the protein-of-interest was detected in the rats, indicating that the vaccine had
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stimulated the expected immune response (Stokes et al., 2020). More research needs to be done
with self-amplifying mRNA vaccines, but the technology is showing promise, and if a formula is
perfected these vaccines could possibly require much smaller doses than conventional mRNA
vaccines while maintaining high immunogenicity. This experiment was carried out in rats so there
is still significant progress to be made before this vaccine structure can be used for protection
against viral infections in humans.
Recently there have also been studies done concerning the generation of monoclonal
antibodies from mRNA delivered as a passive mRNA vaccine. DNA-mediated antibody treatments
have been tested in the past but suffer from greater safety issues than mRNA vaccines (Thran et al.,
2017). One study looked at the efficacy of anti-rabies and anti-botulinum antibodies in a
prophylactic and therapeutic administration (Thran et al., 2017). The study showed that the
encoded antibodies were effective at preventing the death of infected mice in both prophylactic and
therapeutic delivery schemes (Thran et al., 2017). In the case of botulinum toxin, after an
administration of toxin 4xLD50, 100% of the mice survived when the vaccine was administered 6
hours after the initial infection (Thran et al., 2017). The study also detected antibodies in as little as
2 hours post-treatment (Thran et al., 2017). Future research into mRNA mediated antibody
treatment is still needed, although preliminary research shows promising results. Combining
mRNA-mediated antibody treatment with self-amplifying mRNA technology could lead to high
serum antibody levels that could be effective at preventing or therapeutically treating viral
infections.
Conclusion
mRNA vaccines occupy a unique space in vaccinology: these vaccines are simple, cheap,
and are easily produced for nearly any antigen of interest. The modifiable LNP shells and potent
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immunogenicity make these vaccines potentially viable vaccine candidates for several viral agents.
With the emergency approval of the two COVID-19 vaccines, mRNA vaccines are finally being
used for disease prevention, with great preliminary success. Self-amplifying mRNA vaccines are
still in the early stages of research, although they show promising immunogenicity data. In the
future, mRNA vaccines toward the flu may offer broader protection and faster synthesis than
current vaccine options. Although still early in development, mRNA vaccines are gaining in
popularity and are experiencing broad application due to COVID-19.
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